Home  /  Resource Library  /  Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

ASCO 2020: Results of a phase I study investigating a dual CAR T therapy AUTO3 combined with pembrolizumab for treatment of relapsed diffuse large b-cell lymphoma.